Tarsier Pharma Ltd. is a late clinical-stage biopharmaceutical company focused on the development of novel therapies to address unmet medical needs in blinding inflammatory eye diseases. The Company’s lead product candidate, TRS01, is a steroid-free topical eye drop formulation of dazdotuftide — a novel immunomodulator — designed to treat non-infectious anterior uveitis (“NIAU”) and uveitic glaucoma without the intraocular pressure (“IOP”) side effects associated with the current steroid-based standard of care. TRS01 has completed a head-to-head Phase 3 trial (TRS4Vision) against steroids and is backed by an FDA Special Protocol Assessment (“SPA”) agreement for the planned pivotal Tarsier-04 Phase 3 trial, with IOP safety superiority to steroids as the primary endpoint. The Company is also advancing TRS02, an intravitreal injection formulation of dazdotuftide targeting back-of-the-eye blinding diseases including diabetic macular edema, non-proliferative diabetic retinopathy, and dry age-related macular degeneration. Tarsier is headquartered in Zichron Yaacov, Israel.